<p>西氏医药服务（NYSE:WST - 获取免费报告）的股票在周二的报告中被 Stephens 重申了 “增持” 评级，Benzinga 报道。他们目前对该医疗器械供应商的股票设定了 360.00 美元的目标价。Stephens 的目标价表明该股票相较于前一交易日收盘价有 13.97% 的潜在上涨空间。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他一些分析师也对该股票发表了看法。Evercore 在 4 月 24 日的报告中重申了对西氏医药服务股票的 “跑赢大盘” 评级。摩根士丹利将西氏医药服务的目标价从 315.00 美元上调至 325.00 美元，并在周五的报告中给予该公司 “持平” 评级。德意志银行在 2 月 13 日的报告中重申了 “买入” 评级，并对西氏医药服务的股票设定了 315.00 美元的目标价。巴克莱在 4 月 27 日的报告中将西氏医药服务的目标价从 275.00 美元上调至 310.00 美元，并给予该股票 “持平” 评级。最后，Zacks Research 在 5 月 13 日的报告中将西氏医药服务的评级从 “持有” 上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，九位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 327.60 美元。</p>
<p><strong>查看我们关于 WST 的最新研究报告</strong></p>
<h2>西氏医药服务股票表现</h2>
<ul>
<li>今年哪些因素将推动标准普尔 500 指数表现？</li>
</ul>
<p>西氏医药服务的股票在周二开盘价为 315.87 美元。该公司的债务与股本比率为 0.07，流动比率为 2.71，速动比率为 2.04。该公司的市值为 223.2 亿美元，市盈率为 42.23，市盈增长比率为 2.70，贝塔系数为 1.18。该公司的 50 日简单移动平均线为 285.07 美元，200 日简单移动平均线为 267.94 美元。西氏医药服务的 52 周低点为 206.19 美元，52 周高点为 330.88 美元。</p>
<p>西氏医药服务（NYSE:WST - 获取免费报告）最近在 4 月 23 日发布了季度财报。该医疗器械供应商报告本季度每股收益为 2.13 美元，超出分析师一致预期的 1.68 美元，超出幅度为 0.45 美元。该季度的营业收入为 8.449 亿美元，而分析师预期为 7.7968 亿美元。西氏医药服务的净利润率为 16.85%，股本回报率为 19.03%。与去年同期相比，西氏医药服务本季度的收入增长了 21.0%。去年同期，该公司的每股收益为 1.45 美元。西氏医药服务已将 2026 财年的指导目标设定为每股收益 8.400-8.750 美元，2026 年第二季度的指导目标设定为每股收益 2.050-2.120 美元。卖方分析师预测西氏医药服务在当前财年将实现每股收益 8.6 美元。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>西氏医药服务宣布其董事会已于 2 月 17 日授权一项股票回购计划，允许公司回购 10 亿美元的流通股。该回购授权允许该医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席会计官 Chad Winters 在 4 月 27 日的交易中出售了 896 股西氏医药服务的股票。这些股票的平均售价为 300.67 美元，总交易额为 269,400.32 美元。交易后，首席会计官直接持有该公司 1,523 股股票，价值 457,920.41 美元。这笔交易代表其持股比例减少了 37.04%。该销售在向 SEC 提交的文件中披露，文件可通过此超链接获取。此外，副总裁 Annette F. Favorite 在 4 月 27 日的交易中出售了 2,817 股西氏医药服务的股票。该股票的平均售价为 305.20 美元，总交易额为 859,748.40 美元。交易后，副总裁直接持有该公司 16,828 股股票，价值约 5,135,905.60 美元。这代表其持股比例减少了 14.34%。该销售的 SEC 文件提供了更多信息。公司内部人士持有公司股票的 0.60%。</p>
<h2>对西氏医药服务的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近对其在 WST 的持仓进行了调整。Elyxium Wealth LLC 在第四季度购买了西氏医药服务的新股份，价值 25,000 美元。Bayban 在第四季度购买了西氏医药服务的新股份，价值 27,000 美元。Private Trust Co. NA 在第四季度将其在西氏医药服务的持仓提高了 156.4%。Private Trust Co. NA 现在持有该医疗器械供应商 100 股股票，价值 28,000 美元，此前在上个季度又购买了 61 股。DV Equities LLC 在第四季度购买了西氏医药服务的新股份，价值 28,000 美元。最后，Cornerstone Planning Group LLC 在第一季度将其在西氏医药服务的持仓提高了 90.9%。Cornerstone Planning Group LLC 现在持有该医疗器械供应商 105 股股票，价值 26,000 美元，此前在上个季度又购买了 50 股。93.90% 的股票由机构投资者持有。</p>
<h2>西氏医药服务公司简介</h2>
<p>（获取免费报告）</p>
<p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专业药物输送设备。西氏以其弹性密封件、密封条和聚合物组件而闻名，这些产品能够保持无菌性并与敏感药物配方兼容。</p>
<p>除了组件制造，西氏还提供工程化输送系统和产品生命周期内的支持服务。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而非西氏医药服务</li>
<li>投资 Pony AI 股票的五个理由——以及一个等待的理由</li>
<li>SpaceX IPO 是否会让这五只公共航天股票进入更高的轨道？</li>
<li>Palantir 的无人机顺风助力其国防 AI 故事重新引起投资者关注</li>
<li>为什么一只鲜为人知的 ETF 正在利用 AI 芯片短缺</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于西氏医药服务吗？</h2>
<p>在考虑西氏医药服务之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

<p>斯蒂芬斯重申了对西氏医药服务（West Pharmaceutical Services，WST）的 “增持” 评级，目标价为 360 美元，意味着有 13.97% 的上涨空间。其他分析师如 Evercore、摩根士丹利和德意志银行也维持了积极的评级或提高了目标价。WST 最近以每股收益 2.13 美元和 8.449 亿美元的收入超出了第一季度的盈利预期。该公司授权了一项 10 亿美元的股票回购计划。最近 CAO Chad Winters 和副总裁 Annette Favorite 的内部销售被披露</p>

<p>West Pharmaceutical Services (NYSE:WST - Get Free Report)'s stock had its &#34;overweight&#34; rating reaffirmed by Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $360.00 price objective on the medical instruments supplier's stock. Stephens' price objective indicates a potential upside of 13.97% from the stock's previous close.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）的股票在周二的报告中被 Stephens 重申了 “增持” 评级，Benzinga 报道。他们目前对该医疗器械供应商的股票设定了 360.00 美元的目标价。Stephens 的目标价表明该股票相较于前一交易日收盘价有 13.97% 的潜在上涨空间。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>A number of other analysts have also weighed in on the stock. Evercore reissued an &#34;outperform&#34; rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Morgan Stanley raised their price target on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an &#34;equal weight&#34; rating in a report on Friday. Deutsche Bank Aktiengesellschaft reissued a &#34;buy&#34; rating and issued a $315.00 price target on shares of West Pharmaceutical Services in a report on Friday, February 13th. Barclays lifted their target price on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the stock an &#34;equal weight&#34; rating in a report on Monday, April 27th. Finally, Zacks Research raised shares of West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $327.60.</p>
<div class="lb-trans"><p>其他一些分析师也对该股票发表了看法。Evercore 在 4 月 24 日的报告中重申了对西氏医药服务股票的 “跑赢大盘” 评级。摩根士丹利将西氏医药服务的目标价从 315.00 美元上调至 325.00 美元，并在周五的报告中给予该公司 “持平” 评级。德意志银行在 2 月 13 日的报告中重申了 “买入” 评级，并对西氏医药服务的股票设定了 315.00 美元的目标价。巴克莱在 4 月 27 日的报告中将西氏医药服务的目标价从 275.00 美元上调至 310.00 美元，并给予该股票 “持平” 评级。最后，Zacks Research 在 5 月 13 日的报告中将西氏医药服务的评级从 “持有” 上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，九位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 327.60 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on WST</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 WST 的最新研究报告</strong></p>
</div><h2>West Pharmaceutical Services Stock Performance</h2>
<div class="lb-trans"><h2>西氏医药服务股票表现</h2>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年哪些因素将推动标准普尔 500 指数表现？</li>
</ul>
</div><p>Shares of West Pharmaceutical Services stock opened at $315.87 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The firm has a market cap of $22.32 billion, a P/E ratio of 42.23, a P/E/G ratio of 2.70 and a beta of 1.18. The firm has a 50 day simple moving average of $285.07 and a 200 day simple moving average of $267.94. West Pharmaceutical Services has a fifty-two week low of $206.19 and a fifty-two week high of $330.88.</p>
<div class="lb-trans"><p>西氏医药服务的股票在周二开盘价为 315.87 美元。该公司的债务与股本比率为 0.07，流动比率为 2.71，速动比率为 2.04。该公司的市值为 223.2 亿美元，市盈率为 42.23，市盈增长比率为 2.70，贝塔系数为 1.18。该公司的 50 日简单移动平均线为 285.07 美元，200 日简单移动平均线为 267.94 美元。西氏医药服务的 52 周低点为 206.19 美元，52 周高点为 330.88 美元。</p>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. West Pharmaceutical Services's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Sell-side analysts predict that West Pharmaceutical Services will post 8.6 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）最近在 4 月 23 日发布了季度财报。该医疗器械供应商报告本季度每股收益为 2.13 美元，超出分析师一致预期的 1.68 美元，超出幅度为 0.45 美元。该季度的营业收入为 8.449 亿美元，而分析师预期为 7.7968 亿美元。西氏医药服务的净利润率为 16.85%，股本回报率为 19.03%。与去年同期相比，西氏医药服务本季度的收入增长了 21.0%。去年同期，该公司的每股收益为 1.45 美元。西氏医药服务已将 2026 财年的指导目标设定为每股收益 8.400-8.750 美元，2026 年第二季度的指导目标设定为每股收益 2.050-2.120 美元。卖方分析师预测西氏医药服务在当前财年将实现每股收益 8.6 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services declared that its Board of Directors has authorized a share repurchase program on Tuesday, February 17th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its stock is undervalued.</p>
<div class="lb-trans"><p>西氏医药服务宣布其董事会已于 2 月 17 日授权一项股票回购计划，允许公司回购 10 亿美元的流通股。该回购授权允许该医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company's stock, valued at $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席会计官 Chad Winters 在 4 月 27 日的交易中出售了 896 股西氏医药服务的股票。这些股票的平均售价为 300.67 美元，总交易额为 269,400.32 美元。交易后，首席会计官直接持有该公司 1,523 股股票，价值 457,920.41 美元。这笔交易代表其持股比例减少了 37.04%。该销售在向 SEC 提交的文件中披露，文件可通过此超链接获取。此外，副总裁 Annette F. Favorite 在 4 月 27 日的交易中出售了 2,817 股西氏医药服务的股票。该股票的平均售价为 305.20 美元，总交易额为 859,748.40 美元。交易后，副总裁直接持有该公司 16,828 股股票，价值约 5,135,905.60 美元。这代表其持股比例减少了 14.34%。该销售的 SEC 文件提供了更多信息。公司内部人士持有公司股票的 0.60%。</p>
</div><h2>Hedge Funds Weigh In On West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>对西氏医药服务的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in WST. Elyxium Wealth LLC bought a new stake in West Pharmaceutical Services in the 4th quarter valued at $25,000. Bayban bought a new stake in West Pharmaceutical Services in the 4th quarter valued at $27,000. Private Trust Co. NA lifted its position in West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 61 shares in the last quarter. DV Equities LLC bought a new stake in West Pharmaceutical Services in the 4th quarter valued at $28,000. Finally, Cornerstone Planning Group LLC lifted its position in West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 50 shares in the last quarter. 93.90% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对其在 WST 的持仓进行了调整。Elyxium Wealth LLC 在第四季度购买了西氏医药服务的新股份，价值 25,000 美元。Bayban 在第四季度购买了西氏医药服务的新股份，价值 27,000 美元。Private Trust Co. NA 在第四季度将其在西氏医药服务的持仓提高了 156.4%。Private Trust Co. NA 现在持有该医疗器械供应商 100 股股票，价值 28,000 美元，此前在上个季度又购买了 61 股。DV Equities LLC 在第四季度购买了西氏医药服务的新股份，价值 28,000 美元。最后，Cornerstone Planning Group LLC 在第一季度将其在西氏医药服务的持仓提高了 90.9%。Cornerstone Planning Group LLC 现在持有该医疗器械供应商 105 股股票，价值 26,000 美元，此前在上个季度又购买了 50 股。93.90% 的股票由机构投资者持有。</p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西氏医药服务公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专业药物输送设备。西氏以其弹性密封件、密封条和聚合物组件而闻名，这些产品能够保持无菌性并与敏感药物配方兼容。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了组件制造，西氏还提供工程化输送系统和产品生命周期内的支持服务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait</li>
<li>Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?</li>
<li>Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors</li>
<li>Why 1 Little-Known ETF Is Riding the AI Chip Shortage</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非西氏医药服务</li>
<li>投资 Pony AI 股票的五个理由——以及一个等待的理由</li>
<li>SpaceX IPO 是否会让这五只公共航天股票进入更高的轨道？</li>
<li>Palantir 的无人机顺风助力其国防 AI 故事重新引起投资者关注</li>
<li>为什么一只鲜为人知的 ETF 正在利用 AI 芯片短缺</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑西氏医药服务之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

West Pharmaceutical Services' (WST) "Overweight" Rating Reiterated at Stephens

Market Beat

摩根士丹利

德意志银行

巴克莱银行

标普 500 指数

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Stephens 重申了对西氏医药服务（WST）的 “增持” 评级